Striking the target in iron overload disorders

Journal of Clinical Investigation

Volumn 123, Issue 4, 2013, Pages 1424-1427

  Finberg, Karin E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HEPCIDIN; IRON; LIVER PROTEIN; TMPRSS6 PROTEIN; UNCLASSIFIED DRUG;

BETA THALASSEMIA; DISEASE SEVERITY; DRUG TARGETING; GENE MUTATION; HEMOCHROMATOSIS; IRON BALANCE; IRON OVERLOAD; IRON TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BETA-THALASSEMIA; FEMALE; HEMOCHROMATOSIS; MALE; MEMBRANE PROTEINS; SERINE ENDOPEPTIDASES;

EID: 84875829125     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68889     Document Type: Review

References (18)

1. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443.
2. Ginzburg Y, Rivella S. beta-thalassemia: A model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011; 118(16):4321-4330.
3. Gardenghi S, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 2010; 120(12):4466-4477.
4. Nicolas G, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet. 2003;34(1):97-101.
5. Moran-Jimenez MJ, et al. Hepcidin treatment in Hfe-/-mice diminishes plasma iron without affecting erythropoiesis. Eur J Clin Invest. 2010;40(6):511-517.
6. Preza GC, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011;121(12):4880-4888.
7. Guo S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and ®-thalassemia in mice. J Clin Invest. 2013;123(4):1531-1541.
8. Du X, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008; 320(5879):1088-1092.
9. Silvestri L, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008; 8(6):502-511.
10. Finberg KE, Whittlesey RL, Andrews NC. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood. 2011;117(17):4590-4599.
11. Nai A, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood. 2012;119(21):5021-5029.
12. Bennett CF, Swayze EE. RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259-293.
13. Li H, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16(2):177-182.
14. Schmidt PJ, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/-mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood. 2013; 121(7):1200-1208.
15. Sisay MT, et al. Identification of the first low-molecular-weight inhibitors of matriptase-2. J Med Chem. 2010;53(15):5523-5535.
16. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328-343.
17. Kwiatkowski JL. Real-world use of iron chelators. Hematology Am Soc Hematol Educ Program. 2011; 2011:451-458.
18. Weatherall DJ. The definition and epidemiology of non-transfusion- dependent thalassemia. Blood Rev. 2012;26(suppl 1):S3-S6.